Here is a structured market overview of the Inflammatory Bowel Disease (IBD) Treatment Market with company references and quantified insights:

Inflammatory Bowel Disease (IBD) Treatment Market
Market Size & Key Companies
Market size: USD 20.74 billion (2023) → projected USD 27.73 billion by 2030 (CAGR 3.8%)
Key companies:
AbbVie Inc. (Humira, Skyrizi)
Johnson & Johnson Services, Inc.
Takeda Pharmaceutical Company Limited
Pfizer Inc.
Biogen
Novartis AG
Eli Lilly and Company
UCB S.A.
Celltrion Inc.
Merck & Co., Inc.
Recent Developments
AbbVie received regulatory approvals for Skyrizi (UC & Crohn’s) expanding biologics portfolio.
Eli Lilly acquired Morphic Holding (~$3.2B) to strengthen oral IBD pipeline.
Pfizer launched Velsipity (etrasimod) – oral S1P modulator for ulcerative colitis.
Increased biosimilar launches (e.g., Hadlima – Humira biosimilar) improving affordability.
Drivers
Rising prevalence of Crohn’s disease & ulcerative colitis (~5 million UC cases globally)
Strong adoption of biologics (≈52% market share in 2024)
Growing approvals of JAK inhibitors & S1P modulators
Increasing diagnosis rates and awareness
https://www.thebrainyinsights.com/report/inflammatory-bowel-disease-treatment-market-12607

Restraints
High cost of biologic therapies limiting access
Stringent regulatory approvals delaying product launches
Availability of alternative treatments (surgery, diet, probiotics)
Patent expiries → pricing pressure due to biosimilars
Regional Segmentation Analysis
North America
Largest share: 57.59% (2023)
Driven by strong pharma presence (AbbVie, Pfizer, J&J)
Europe
Mature market with high biologics adoption
Asia-Pacific
Fastest growing region due to rising healthcare spending and patient pool
Latin America & MEA
Emerging markets with improving access
Emerging Trends
Shift toward targeted therapies & precision medicine
Rapid growth of biosimilars and monoclonal antibodies
Development of oral biologics alternatives
Integration of AI in clinical trials & diagnosis
Expansion of online pharmacies & self-administered injectables
Top Use Cases
Treatment of:
Crohn’s disease (≈60.6% market share)
Ulcerative colitis
Drug classes:
TNF inhibitors (≈36.9% share)
Immunosuppressants
Corticosteroids
Biologics & biosimilars
End users:
Hospitals
Specialty clinics
Homecare (self-injectables)
Major Challenges
Long-term safety concerns of immunosuppressants
Lack of permanent cure (chronic disease management)
Patient variability in drug response
High treatment discontinuation rates
Complex clinical trial requirements
Attractive Opportunities
Expansion of biosimilars market (cost reduction)
Development of oral therapies (non-injectable biologics)
Growth in Asia-Pacific healthcare infrastructure
Personalized medicine & biomarker-driven therapies
Strategic collaborations & M&A among pharma companies
Key Factors of Market Expansion
Increasing R&D investments in biologics & novel drugs
Strong pipeline of advanced therapies (JAK, S1P, monoclonal antibodies)
Rising healthcare expenditure globally
Improved reimbursement policies in developed markets
Growth of telemedicine & digital healthcare platforms
If you want, I can also provide a competitive benchmarking (market share %, revenue by company, pipeline drugs) or a Porter’s Five Forces analysis for this market.